Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Receivables: 2011-2025

Historic Change in Receivables for Adma Biologics (ADMA) over the last 11 years, with Sep 2025 value amounting to $27.9 million.

  • Adma Biologics' Change in Receivables rose 39.55% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.5 million, marking a year-over-year increase of 365.08%. This contributed to the annual value of $22.6 million for FY2024, which is 89.48% up from last year.
  • As of Q3 2025, Adma Biologics' Change in Receivables stood at $27.9 million, which was up 171.00% from $10.3 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Change in Receivables ranged from a high of $49.4 million in Q1 2025 and a low of -$19.5 million during Q2 2024.
  • For the 3-year period, Adma Biologics' Change in Receivables averaged around $11.1 million, with its median value being $10.3 million (2025).
  • Its Change in Receivables has fluctuated over the past 5 years, first plummeted by 1,654.71% in 2021, then surged by 473.67% in 2023.
  • Quarterly analysis of 5 years shows Adma Biologics' Change in Receivables stood at $8.2 million in 2021, then plummeted by 165.95% to -$5.4 million in 2022, then increased by 27.78% to -$3.9 million in 2023, then surged by 96.38% to -$141,000 in 2024, then surged by 39.55% to $27.9 million in 2025.
  • Its last three reported values are $27.9 million in Q3 2025, $10.3 million for Q2 2025, and $49.4 million during Q1 2025.